Patents by Inventor Patrick Sinn

Patrick Sinn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250144247
    Abstract: Method to enhance the delivery of one or more gene therapy vectors to cells comprising contacting said cells with a hypertonic solution before. after or simultaneously with said one or more gene therapy vectors.
    Type: Application
    Filed: November 4, 2024
    Publication date: May 8, 2025
    Inventors: Ashley Cooney, Patrick Sinn, Paul B. McCray, JR.
  • Publication number: 20230174600
    Abstract: Provided herein are polynucleotides, lentiviral vectors, pharmaceutical compositions, and methods of making and using the same, e.g., for treatment of cystic fibrosis (CF).
    Type: Application
    Filed: April 27, 2021
    Publication date: June 8, 2023
    Inventors: Paul B. McCray, JR., Patrick Sinn, Laura Marquez Lora
  • Patent number: 8703469
    Abstract: A method of co-expressing a portion of the VSV G protein gene or a truncated “stem” portion with GP64 and a retrovirus increases the titer of retroviral vectors. A truncated VSV G protein, preferably comprised of a small segment from the C-terminal portion of the ectodomain plus the transmembrane (TM) and cytoplasmic tail (CTD) domains of VSV G, co-expressed with retroviral vectors, enhances the production titers of the retroviral vectors. A preferred embodiment uses a VSV G construct that includes an N-terminal c-Myc epitope plus 42 amino acids from the C-terminal portion of the ectodomain, 20 amino acids from the predicted TM domain, and 29 amino acids from the predicted CTD of the VSV G protein.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: April 22, 2014
    Assignees: Boyce Thompson Institute for Plant Research, University of Iowa Research Foundation
    Inventors: Paul McCray, Patrick Sinn, Gary Blissard
  • Publication number: 20130065296
    Abstract: A method of co-expressing a portion of the VSV G protein gene or a truncated “stem” portion with GP64 and a retrovirus increases the titer of retroviral vectors. A truncated VSV G protein, preferably comprised of a small segment from the C-terminal portion of the ectodomain plus the transmembrane (TM) and cytoplasmic tail (CTD) domains of VSV G, co-expressed with retroviral vectors, enhances the production titers of the retroviral vectors. A preferred embodiment uses a VSV G construct that includes an N-terminal c-Myc epitope plus 42 amino acids from the C-terminal portion of the ectodomain, 20 amino acids from the predicted TM domain, and 29 amino acids from the predicted CTD of the VSV G protein.
    Type: Application
    Filed: September 13, 2011
    Publication date: March 14, 2013
    Applicants: UNIVERSITY OF IOWA RESEARCH FOUNDATION, BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH
    Inventors: Paul McCray, Patrick Sinn, Gary Blissard
  • Patent number: 7608449
    Abstract: The present invention concerns the methods and compositions related to pseudotyped viral vectors. Embodiments of the invention include pseudotyping expression cassettes that include nucleic acid elements for enhancing the titer of pseudotyped viral particles. Embodiments of the invention include novel methods and compositions related to making high titer pseudotyped retroviral vector compositions. A heterologous envelope glycoprotein is typically incorporated into the virus during the budding or virus production process. Certain embodiments of the invention include pseudotyped retroviral vectors comprising a heterologous envelope glycoprotein derived from a Jaagsiekte sheep retrovirus (JSRV env). Pseudotyped viruses or viral particles may have a modified host range that is influenced by the properties of the heterologous envelope glycoprotein.
    Type: Grant
    Filed: May 13, 2004
    Date of Patent: October 27, 2009
    Assignees: The Regents of the University of California, The University of Iowa Research Foundation
    Inventors: Paul McCray, Hung Fan, Patrick Sinn
  • Publication number: 20060154240
    Abstract: Embodiments of the invention include compositions comprising and methods utilizing a retroviral integrase complex comprising a recombinant integrase having a domain comprising a non-native protein binding site, and a DNA binding protein comprising a DNA binding domain and a peptide binding domain that binds the non-native protein binding site of the recombinant integrase.
    Type: Application
    Filed: December 22, 2005
    Publication date: July 13, 2006
    Inventors: Paul McCray, Patrick Sinn, Daniel Voytas, Junbiao Dai
  • Publication number: 20060084620
    Abstract: The present invention is directed to small interfering RNA molecules targeted against a gene of interest in respiratory epithelial cells, and methods of using these RNA molecules.
    Type: Application
    Filed: July 11, 2005
    Publication date: April 20, 2006
    Inventors: Paul McCray, Beverly Davidson, Anthony Fischer, Hong Jia, Maureen Donovan, Patrick Sinn, Mark Behlke
  • Publication number: 20050112098
    Abstract: The invention provides a method to introduce a selected nucleic acid sequence into an airway epithelial cell that involves contacting the airway epithelial cell with a pseudotyped retrovirus that includes a glycoprotein in which a portion of an O-glycosylation region within the glycoprotein has been deleted and a retroviral capsid that includes the selected nucleic acid sequence. The invention also provides a method to reduce or eliminate the symptoms of cystic fibrosis in a mammal that involves contacting an airway epithelial cell of the mammal with a pseudotyped retrovirus that includes a glycoprotein in which a portion of an O-glycosylation region within the glycoprotein has been deleted and a retroviral capsid that includes a nucleic acid sequence that encodes a cystic fibrosis transmembrane regulator protein.
    Type: Application
    Filed: March 26, 2004
    Publication date: May 26, 2005
    Applicants: Purdue Research Foundation, University of Iowa Research Foundation
    Inventors: Paul McCray, David Sanders, Scott Jeffers, Beverly Davidson, Patrick Sinn
  • Publication number: 20040265798
    Abstract: The present invention concerns the methods and compositions related to pseudotyped viral vectors. Embodiments of the invention include pseudotyping expression cassettes that include nucleic acid elements for enhancing the titer of pseudotyped viral particles. Embodiments of the invention include novel methods and compositions related to making high titer pseudotyped retroviral vector compositions. A heterologous envelope glycoprotein is typically incorporated into the virus during the budding or virus production process. Certain embodiments of the invention include pseudotyped retroviral vectors comprising a heterologous envelope glycoprotein derived from a Jaagsiekte sheep retrovirus (JSRV env). Pseudotyped viruses or viral particles may have a modified host range that is influenced by the properties of the heterologous envelope glycoprotein.
    Type: Application
    Filed: May 13, 2004
    Publication date: December 30, 2004
    Applicants: The University of Iowa Research Foundation, The Regents of the University of California, a California Corporation
    Inventors: Paul McCray, Hung Fan, Patrick Sinn